Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer
- PMID: 25706985
- PMCID: PMC4338247
- DOI: 10.1371/journal.pone.0118210
Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer
Abstract
V-Raf Murine Sarcoma Viral Oncogene Homolog B (BRAF) mutated lung cancer is relatively aggressive and is resistant to currently available therapies. In a recent phase II study for patients with BRAF-V600E non-small cell lung cancer (NSCLC), BRAF V600E inhibitor demonstrated evidence of activity, but 30% of this selected group progressed while on treatment, suggesting a need for developing alternative strategies. We tested two different options to enhance the efficacy of vemurafenib (BRAF V600E inhibitor) in BRAF mutated NSCLC. The first option was the addition of erlotinib to vemurafenib to see whether the combination provided synergy. The second was to induce MEK inhibition (downstream of RAF) with trametinib (MEK inhibitor). We found that the combination of vemurafenib and erlotinib was not synergistic to the inhibition of p-ERK signaling in BRAF-V600E cells. Vemurafenib caused significant apoptosis, G1 arrest and upregulation of BIM in BRAF-V600 cells. Trametinib was effective as a single agent in BRAF mutated cells, either V600E or non-V600E. Finally, the combination of vemurafenib and trametinib caused a small but significant increase in apoptosis as well as a significant upregulation of BIM when compared to either single agent. Thus, hinting at the possibility of utilizing a combinational approach for the management of this group of patients. Importantly, trametinib alone caused upregulation of p-AKT in BRAF non-V600 mutated cells, while this effect was nullified with the combination. This finding suggests that, the combination of a MEK inhibitor with a BRAF inhibitor will be more efficacious in the clinical setting for patients with BRAF mutated NSCLC.
Conflict of interest statement
Figures




Similar articles
-
Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.Cancer Res. 2012 Feb 1;72(3):779-89. doi: 10.1158/0008-5472.CAN-11-2941. Epub 2011 Dec 16. Cancer Res. 2012. PMID: 22180495
-
Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.Lancet Oncol. 2015 Oct;16(13):1389-98. doi: 10.1016/S1470-2045(15)00087-X. Lancet Oncol. 2015. PMID: 26433819 Clinical Trial.
-
Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial.Lancet Oncol. 2016 Jul;17(7):984-993. doi: 10.1016/S1470-2045(16)30146-2. Epub 2016 Jun 6. Lancet Oncol. 2016. PMID: 27283860 Free PMC article. Clinical Trial.
-
Dabrafenib in combination with trametinib in the treatment of patients with BRAF V600-positive advanced or metastatic non-small cell lung cancer: clinical evidence and experience.Ther Adv Respir Dis. 2018 Jan-Dec;12:1753466618767611. doi: 10.1177/1753466618767611. Ther Adv Respir Dis. 2018. PMID: 29595366 Free PMC article. Review.
-
Therapeutic potential of trametinib to inhibit the mutagenesis by inactivating the protein kinase pathway in non-small cell lung cancer.Expert Rev Anticancer Ther. 2019 Jan;19(1):11-17. doi: 10.1080/14737140.2019.1554440. Epub 2018 Dec 4. Expert Rev Anticancer Ther. 2019. PMID: 30513023 Review.
Cited by
-
Pan-RAF and MEK vertical inhibition enhances therapeutic response in non-V600 BRAF mutant cells.BMC Cancer. 2018 May 8;18(1):542. doi: 10.1186/s12885-018-4455-x. BMC Cancer. 2018. PMID: 29739364 Free PMC article.
-
[Progress in the Treatment of Non-small Cell Lung Cancer with BRAF Inhibitors].Zhongguo Fei Ai Za Zhi. 2016 Oct 20;19(10):711-714. doi: 10.3779/j.issn.1009-3419.2016.10.13. Zhongguo Fei Ai Za Zhi. 2016. PMID: 27760604 Free PMC article. Review. Chinese.
-
Emerging Targeted Therapies for the Treatment of Non-small Cell Lung Cancer.Curr Oncol Rep. 2019 Feb 26;21(3):21. doi: 10.1007/s11912-019-0770-x. Curr Oncol Rep. 2019. PMID: 30806814 Review.
-
Current Molecular-Targeted Therapies in NSCLC and Their Mechanism of Resistance.Cancers (Basel). 2018 Jul 4;10(7):224. doi: 10.3390/cancers10070224. Cancers (Basel). 2018. PMID: 29973561 Free PMC article. Review.
-
Personalizing Therapy Outcomes through Mitogen-Activated Protein Kinase Pathway Inhibition in Non-Small Cell Lung Cancer.Biomedicines. 2024 Jul 5;12(7):1489. doi: 10.3390/biomedicines12071489. Biomedicines. 2024. PMID: 39062063 Free PMC article. Review.
References
-
- Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, et al. (2007) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316: 1039–1043. - PubMed
-
- Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, et al. (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353: 123–132. - PubMed
-
- Zhou C, Wu YL, Chen G, Feng J, Liu XQ, et al. (2011) Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 12: 735–742. 10.1016/S1470-2045(11)70184-X - DOI - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous